

## Tecentriq® (atezolizumab) - New indication

- On March 18, 2019, <u>Genentech announced</u> the FDA approval of <u>Tecentriq (atezolizumab)</u>, in combination with <u>carboplatin</u> and <u>etoposide</u>, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
- Tecentriq is also approved for the treatment of patients with urothelial carcinoma, non-small cell lung cancer (NSCLC), and triple-negative breast cancer.
- According to the American Cancer Society, it is estimated that more than 228,000 Americans will be diagnosed with lung cancer in 2019. SCLC accounts for approximately 13% of all cases.
   Approximately 70% of people with SCLC are diagnosed with ES-SCLC.
- The approval of Tecentriq's new indication was based on IMpower133, a double-blind study in 403
  patients with ES-SCLC. Patients were randomized to receive Tecentriq + carboplatin + etoposide or
  placebo + carboplatin + etoposide. Major efficacy outcome measures were overall survival (OS) and
  progression-free survival (PFS).
  - Median OS was 12.3 months for the Tecentriq arm vs. 10.3 months for the placebo arm (Hazard Ratio [HR] 0.70; 95% CI: 0.54, 0.91; p = 0.0069).
  - Medan PFS was 5.2 months for the Tecentriq arm vs. 4.3 months for the placebo arm (HR 0.77; 95% CI: 0.62, 0.96; p = 0.017).
  - The objective response rate was 60% (95% CI: 53, 67) for the Tecentriq arm vs. 64% (95% CI: 57, 71) for the placebo arm.
  - The median duration of response was 4.2 months (95% CI: 4.1, 4.5) for the Tecentriq arm vs. 3.9 months (95% CI: 3.1, 4.2) for the placebo arm.
- The most common adverse reactions (≥ 20%) with Tecentriq in combination with other antineoplastic drugs in patients with NSCLC and SCLC were fatigue/asthenia, nausea, alopecia, constipation, diarrhea, and decreased appetite.
- The recommended dosage of Tecentriq for SCLC is 1200 mg intravenously over 60 minutes every 3
  weeks until disease progression or unacceptable toxicity.
  - When administering Tecentriq in combination with chemotherapy, administer Tecentriq prior to chemotherapy when given on the same day.
  - Refer to the drug labels for the chemotherapy agents administered in combination with Tecentriq for additional recommended dosing information
- Refer to the Tecentriq drug label for dosing recommendations for its other indications.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.